Trial Profile

A Phase 1b/2 study of IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC in China

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palverafusp alfa (Primary) ; Antineoplastics
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

31 Jul 2025 According to Instil Bio media release, ImmuneOnco expects to present updated safety and efficacy data at a future medical conference
31 Jul 2025 According to Instil Bio media release, Professor Caicun Zhou, M.D., Ph.D. is the lead investigator of the study.
31 Jul 2025 Results published in the Instil Bio Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com